businessbriefs
Founder

Jan van de Winkel

1
brief
9:24
average
9 min
in total
On business.briefs1
video still
9:24

Genmab

Jan van de Winkel · 1998

Genmab is a platform biotech — not a drug developer — built around two licensed and proprietary antibody generation methods. Its value is in reducing discovery risk and time, not in owning clinical or commercial outcomes.